Results
Shukra Pharmaceuticals Q4 Net Loss of ₹1.73 Crore
Board approved audited standalone and consolidated financial results for Q4 and FY ending March 31, 2026, reporting a net loss of ₹1.73 crore for the quarter.
Recommended a final dividend of ₹0.01 per
